Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
about
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITAutoinhibition of the insulin-like growth factor I receptor by the juxtamembrane regionCell signaling by receptor tyrosine kinasesDiscovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyGenetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumorsEmerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsStructural and functional properties of platelet-derived growth factor and stem cell factor receptorsPrimary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal locationFunctional deregulation of KIT: link to mast cell proliferative diseases and other neoplasmsExploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaA Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine KinasesSmall Molecule Recognition of c-Src via the Imatinib-Binding ConformationCrystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG ConformationA crystallographic snapshot of tyrosine trans-phosphorylation in actionKIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patientsThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase ConformationsA G-Rich Sequence within the c-kit Oncogene Promoter Forms a Parallel G-Quadruplex Having Asymmetric G-Tetrad DynamicsA conserved mechanism of autoinhibition for the AMPK kinase domain: ATP-binding site and catalytic loop refolding as a means of regulationStructural Basis for c-KIT Inhibition by the Suppressor of Cytokine Signaling 6 (SOCS6) Ubiquitin LigaseMolecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsDiscovery of Potent and Selective Covalent Inhibitors of JNKNovel Binding Mode of a Potent and Selective Tankyrase InhibitorSequence Determinants of a Specific Inactive Protein Kinase ConformationStructural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal regionStructural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase InhibitorsMolecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDRole of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insightA Src-like inactive conformation in the abl tyrosine kinase domainSteered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and AblMutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanismsTyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocketHotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivityInsight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KITComputational modeling of laminin N-terminal domains using sparse distance constraints from disulfide bonds and chemical cross-linkingHierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.
P2860
Q21142738-CA03E2E3-BAD3-48E3-AE46-85C713467670Q24313159-912E8D3F-F9A3-49C8-8912-12CAE23C03B5Q24598357-C574C72D-7834-4D33-BCDA-4272F91145DBQ24608143-A6C3B6CF-B764-4E40-92C3-5D6E14194C3EQ24685914-CDA1F67B-C8B4-40E5-ACC8-1D6901ACB412Q26738567-BEC8E568-7112-4E39-8B26-0AACE2B44B2AQ26799387-25A87BA9-CBAD-4B19-914A-F284E3BACDEEQ26829546-278F2FD5-87D8-4C9D-BDED-C6BADC5C81E8Q26829970-4FBB8183-BF8E-492E-B92A-AED53B547A77Q26995624-967107B1-3105-44EC-8664-DDF4028D3DCDQ27001584-D8689020-EFCB-4B05-A650-8207FA14C609Q27640723-EA7FDCA1-BDD0-4D2B-A7DD-9E50FCEE8CAAQ27647832-26921A57-B45B-45CE-87EC-81AE15D5DD25Q27652602-3209C7FC-10C7-43AC-9EA0-AF81B5E30FBBQ27652985-9BD5D856-2A42-490D-9888-33D49091D435Q27653072-1578DBD6-E981-4E05-BA61-44901FC1C2A5Q27653496-41760913-62D0-462A-B6D1-2D63B7AE73DDQ27653890-7CA7F7D1-30E7-4205-8C72-39F74C4AEF53Q27654059-8D342248-DE7B-432C-A169-40E7B0757B1BQ27657150-F3508E92-47BC-4F01-B6D8-136F659B9CB6Q27659450-49E6FA94-83EC-4922-9BFC-6C768C1FCB80Q27665424-479C3974-E4A4-40E6-93E3-04C974CD6EBDQ27673353-A0DDA18C-B1CE-4192-97F0-C2AF99F3C63EQ27676927-CEF16138-EE8B-4FB2-9A2B-53EA9BA55628Q27678151-F5E3BE8A-2A94-4D7B-B869-16290F97F126Q27678722-951C5095-B6B9-482C-AB63-C0353797B3E2Q27680371-91AA068B-AFB5-424B-8944-122931D156AAQ27683558-E5EDB3FD-F114-4B6A-9DFB-D2A37F27D9BEQ27683971-6D962422-1163-448F-816C-85CB6307158FQ27851767-EDE1D7B5-323B-4ADF-AF26-51FD962E1CD7Q27852087-2A361865-6585-43C6-B339-219D37DAF561Q28293108-E62FF938-71AA-4DCC-91D2-5E27E1ABDE79Q28469170-C6D91408-7920-4F71-B5DB-651F477A96C8Q28472368-8B17A963-0D2F-451B-9C56-9CA608DA8CE9Q28478611-E01EDA58-2975-42B0-9B1B-8D313BC0CC9FQ28486691-EE1DD7DB-05BB-4911-8C1C-78ABCBC43A5DQ28541374-07B12796-6033-433F-83E4-82E6E7BC3397Q28553167-1E757D29-A13C-44CB-957C-A0196B04DB4CQ28821078-F0ABF977-883B-4F68-B8F1-ADEEA7814677Q30157152-8FB782D7-88B1-4AB5-BC21-8D4D8E1FF921
P2860
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
@en
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
@nl
type
label
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
@en
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
@nl
prefLabel
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
@en
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
@nl
P2093
P356
P1476
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
@en
P2093
Bi-Ching Sang
Clifford D Mol
Daniel N Scheibe
Douglas R Dougan
Gyorgy P Snell
Keith P Wilson
Michelle L Kraus
Robert J Skene
P304
31655-31663
P356
10.1074/JBC.M403319200
P407
P577
2004-04-29T00:00:00Z